Taxpayers May Have Overpaid by More Than $1 Billion for Mylan's EpiPen: Senator - NBC 10 Philadelphia

Taxpayers May Have Overpaid by More Than $1 Billion for Mylan's EpiPen: Senator

    processing...

    NEWSLETTERS

    Congress Grills Head of EpiPen on Price Hikes

    Mylan CEO Heather Bresch faces Congress to answer questions on EpiPen price hikes. (Published Wednesday, Sept. 21, 2016)

    American taxpayers may have overpaid by as much as $1.27 billion for EpiPen anti-allergy devices over the course of a decade, a U.S. senator said Wednesday. 

    That is nearly three times the $465 million that EpiPen’s owner, drugmaker Mylan, last October said it agreed to pay the federal government to settle claims it overcharged the government-run Medicaid system for the devices. 

    As CNBC reports, Sen. Chuck Grassley, R-Iowa, said it looks like Mylan overcharged taxpayers for years by knowingly classifying the brand-name EpiPen as a generic drug, resulting in the company paying a lower rebate rate to Medicaid.

    A spokeswoman for Mylan had no immediate comment.